Literature DB >> 29502311

Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment.

Ivayla Apostolova1, Catharina Lange2, Per Suppa3, Lothar Spies3, Susanne Klutmann1, Gerhard Adam1, Michel J Grothe4, Ralph Buchert5.   

Abstract

PURPOSE: Increased blood glucose level (BGL) has been reported to cause alterations of FDG uptake in the brain that mimic Alzheimer's disease (AD), even within the "acceptable" range ≤ 160 mg/dl. The aim of this study was (i) to confirm this in a large sample of well-characterized normal control (NC) subjects, and (ii) to analyze its impact on the prediction of AD dementia (ADD) in mild cognitive impairment (MCI).
METHODS: The study included NCs from the Alzheimer's Disease Neuroimaging Initiative (ADNI) that were cognitively stable for ≥36 months after PET (n = 87, 74.2 ± 5.3 y), and ADNI MCIs with ≥36 months follow-up if not progressed to ADD earlier (n = 323, 71.1 ± 7.1 y). Seventy-three of the MCIs had progressed to ADD within 36 months. In the NCs, parenchyma-scaled FDG uptake was tested for clusters of correlation with BGL on the family-wise, error-corrected 5% level. In the MCIs, ROC analysis was used to assess the power of FDG uptake in a predefined AD-typical region for prediction of ADD. ROC analysis was repeated after correcting mean FDG uptake in the AD-typical region for BGL based on linear regression in the NCs.
RESULTS: In the NCs, BGL (59-149 mg/dl) was negatively correlated with FDG uptake in a cluster comprising the occipital cortex and precuneus but sparing the posterior cingulate, independent of amyloid-β and ApoE4 status. In the MCIs, FDG uptake in the AD-typical region provided an area of 0.804 under the ROC curve for prediction of ADD. Correcting FDG uptake in the AD-typical region for BGL (55-189 mg/dl) did not change predictive performance (area = 0.808, p = 0.311).
CONCLUSIONS: Increasing BGL is associated with relative reduction of FDG uptake in the posterior cortex even in the "acceptable" range ≤ 160 mg/dl. The BGL-associated pattern is similar to the typical AD pattern, but not identical. BGL-associated variability of regional FDG uptake has no relevant impact on the power of FDG PET for prediction of MCI-to-ADD progression.

Entities:  

Keywords:  F-18-fluorodesoxyglucose; Healthy controls; MCI; Plasma glucose

Mesh:

Substances:

Year:  2018        PMID: 29502311     DOI: 10.1007/s00259-018-3985-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  17 in total

1.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.

Authors:  William J Jagust; Dan Bandy; Kewei Chen; Norman L Foster; Susan M Landau; Chester A Mathis; Julie C Price; Eric M Reiman; Daniel Skovronsky; Robert A Koeppe
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

Review 3.  Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  Valentina Garibotto; Karl Herholz; Marina Boccardi; Agnese Picco; Andrea Varrone; Agneta Nordberg; Flavio Nobili; Osman Ratib
Journal:  Neurobiol Aging       Date:  2017-04       Impact factor: 4.673

4.  Alteration of the regional cerebral glucose metabolism in healthy subjects by glucose loading.

Authors:  Kenji Ishibashi; Kei Wagatsuma; Kiichi Ishiwata; Kenji Ishii
Journal:  Hum Brain Mapp       Date:  2016-04-08       Impact factor: 5.038

5.  Plasma Glucose Levels Affect Cerebral 18F-FDG Distribution in Cognitively Normal Subjects With Diabetes.

Authors:  Kenji Ishibashi; Airin Onishi; Yoshinori Fujiwara; Kiichi Ishiwata; Kenji Ishii
Journal:  Clin Nucl Med       Date:  2016-06       Impact factor: 7.794

6.  Reduced uptake of 18F-FDG and 15O-H2O in Alzheimer's disease-related regions after glucose loading.

Authors:  Kenji Ishibashi; Keiichi Kawasaki; Kiichi Ishiwata; Kenji Ishii
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-10       Impact factor: 6.200

7.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

8.  Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease.

Authors:  Vanja Kljajevic; Michel Jan Grothe; Michael Ewers; Stefan Teipel
Journal:  Neurobiol Aging       Date:  2014-04-13       Impact factor: 4.673

9.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

10.  Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.

Authors:  Catharina Lange; Per Suppa; Lars Frings; Winfried Brenner; Lothar Spies; Ralph Buchert
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

View more
  3 in total

1.  Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population.

Authors:  Qiu-Yue Dong; Tao-Ran Li; Xue-Yan Jiang; Xiao-Ni Wang; Ying Han; Jie-Hui Jiang
Journal:  Alzheimers Res Ther       Date:  2021-04-07       Impact factor: 6.982

2.  EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3.

Authors:  Eric Guedj; Andrea Varrone; Ronald Boellaard; Nathalie L Albert; Henryk Barthel; Bart van Berckel; Matthias Brendel; Diego Cecchin; Ozgul Ekmekcioglu; Valentina Garibotto; Adriaan A Lammertsma; Ian Law; Iván Peñuelas; Franck Semah; Tatjana Traub-Weidinger; Elsmarieke van de Giessen; Donatienne Van Weehaeghe; Silvia Morbelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-09       Impact factor: 10.057

3.  18F-Fluorodeoxyglucose Positron Emission Tomography Tracks the Heterogeneous Brain Susceptibility to the Hyperglycemia-Related Redox Stress.

Authors:  Alberto Miceli; Vanessa Cossu; Cecilia Marini; Patrizia Castellani; Stefano Raffa; Maria Isabella Donegani; Silvia Bruno; Silvia Ravera; Laura Emionite; Anna Maria Orengo; Federica Grillo; Flavio Nobili; Silvia Morbelli; Antonio Uccelli; Gianmario Sambuceti; Matteo Bauckneht
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.